Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Rivaroxaban for Treatment of Pediatric Venous Thromboembolism. an Einstein-Jr Phase 3 Dose-Exposure-Response Evaluation

Guy Young, MD, Anthonie WA. Lensing, MD PhD, Paul Monagle, MBBS, MSc, Christoph Male, MD, Dagmar Kubitza, MD

Blood (2019) 134 (Supplement_1): 164.

https://doi.org/10.1182/blood-2019-124873

Published: 2019

Journal Articles

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in the Prevention of Venous Thromboembolism after Elective Hip or Knee Replacement Surgery

Scott D. Berkowitz, MD, Keith A A Fox, MBBS, Stephan Schmidt, Jeffrey I Weitz, MD FRCPC, FACP, Dirk Garmann, Dagmar Kubitza, Wolfgang Mueck, Gary Peters, MD, Isabel Reinecke, Alexander Solms, Theodore E Spiro, MD, Xiaoyu Yan, PhD MSc, Liping Zhang, Stefan Willmann

Blood (2017) 130 (Supplement 1): 3718.

https://doi.org/10.1182/blood.V130.Suppl_1.3718.3718

Published: 2017

Journal Articles

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients Treated for Venous Thromboembolism

Scott D. Berkowitz, MD, Jeffrey I Weitz, MD FRCPC, FACP, Stephan Schmidt, Keith A A Fox, MBBS, Dirk Garmann, Dagmar Kubitza, Wolfgang Mueck, Gary Peters, MD, Isabel Reinecke, Alexander Solms, Theodore E Spiro, MD, Xiaoyu Yan, PhD MSc, Liping Zhang, Stefan Willmann

Blood (2017) 130 (Supplement 1): 1104.

https://doi.org/10.1182/blood.V130.Suppl_1.1104.1104

Published: 2017

Journal Articles

Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban.

Sylvia Haas, MD, Alexander GG Turpie, MD, Michael Rud Lassen, MD, Ajay K Kakkar, MD, PhD, Bengt Eriksson, MD, PhD, Kai Vogtlaender, Dagmar Kubitza, MD, Wolfgang Mueck, PhD, Michael Gent, DSc, Frank Misselwitz, MD, Scott D Berkowitz, MD, FACP

Blood (2009) 114 (22): 2099.

https://doi.org/10.1182/blood.V114.22.2099.2099

Published: 2009

Journal Articles

The Effect of Extreme Age, and Gender, on the Pharmacology and Tolerability of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor.

Dagmar Kubitza, MD, Michael Becka, PhD, Wolfgang Mueck, PhD, Michael Zuehlsdorf, PhD

Blood (2006) 108 (11): 905.

https://doi.org/10.1182/blood.V108.11.905.905

Published: 2006

Journal Articles

Effects of Renal Impairment on the Pharmacology of Rivaroxaban (BAY 59-7939) - An Oral, Direct, Factor Xa Inhibitor.

Atef Halabi, MD, Haidar Maatouk, MD, Norbert Klause, MD, Volkmar Lufft, MD, Dagmar Kubitza, MD, Michael Zuehlsdorf, PhD, Michael Becka, PhD, Wolfgang Mueck, PhD, Rafael Schäfers, MD, Dominic Wand, Thomas Philipp, MD, Heike Bruck, MD

Blood (2006) 108 (11): 913.

https://doi.org/10.1182/blood.V108.11.913.913

Published: 2006

Journal Articles

Effects of Single-Dose BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor - in Subjects with Extreme Body Weight.

Dagmar Kubitza, MD, Michael Becka, MD, Michael Zuehlsdorf, MD, Wolfgang Mueck, MD

Blood (2005) 106 (11): 1872.

https://doi.org/10.1182/blood.V106.11.1872.1872

Published: 2005

Journal Articles

Naproxen Has No Relevant Effect on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

Dagmar Kubitza, MD, PhD, Michael Becka, MD, Wolfgang Mueck, MD, Michael Zuehlsdorf, MD

Blood (2005) 106 (11): 1873.

https://doi.org/10.1182/blood.V106.11.1873.1873

Published: 2005

NARROW

Rivaroxaban for Treatment of Pediatric Venous Thromboembolism. an Einstein-Jr Phase 3 Dose-Exposure-Response Evaluation

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in the Prevention of Venous Thromboembolism after Elective Hip or Knee Replacement Surgery

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients Treated for Venous Thromboembolism

Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban.

The Effect of Extreme Age, and Gender, on the Pharmacology and Tolerability of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor.

Effects of Renal Impairment on the Pharmacology of Rivaroxaban (BAY 59-7939) - An Oral, Direct, Factor Xa Inhibitor.

Effects of Single-Dose BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor - in Subjects with Extreme Body Weight.

Naproxen Has No Relevant Effect on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only